Worrisome trends in rising minimum inhibitory concentration values of antibiotics against methicillin resistant Staphylococcus aureus - Insights from a tertiary care center, South India

Brazilian Journal of Infectious Diseases

Volumn 19, Issue 6, 2015, Pages 585-589

  Niveditha, Nagasundaram ^a   Sujatha, Sistla ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

MIC creep; MRSA; Vancomycin; VISA

Indexed keywords

DAPTOMYCIN; LINEZOLID; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; METICILLIN; MINOCYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; INDIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC50; MIC90; NONHUMAN; TERTIARY CARE CENTER; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HUMAN; LD50; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; INDIA; LETHAL DOSE 50; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TERTIARY CARE CENTERS; VANCOMYCIN;

EID: 84949087101     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2015.08.005     Document Type: Article

References (21)

1. Scott T.M. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007, 45:S184-S190.
2. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292.
3. Arbeit R.D., Maki D., Tally F.P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
4. Greer N.D. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006, 19:155-161.
5. Zorgani A., Elahmer O., Ziglam H., et al. In-vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus isolated from wounds of burn patients in Tripoli-Libya. J Microbiol Infect Dis 2012, 2:109-112.
6. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: Twenty-fourth Informational Supplement M100-S24 2014, CLSI, Wayne, PA, USA.
7. The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0 2014, http://www.eucast.org.
8. Menezes G.A., Harish B.N., Sujatha S., et al. Emergence of vancomycin intermediate Staphylococcus species in southern India. J Med Microbiol 2008, 57:911-912.
9. Thati V., Channappa T., Shivannavar, et al. Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J Med Res 2011, 134:704-708.
10. Rybak M.J., Lomaestro B.M., Rotscahfer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
11. Holland T.L., Fowler V.G. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?. J Infect Dis 2011, 204:329-331.
12. Jacob J.T., DiazGranados C.A. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 2013, 17:e93-e100.
13. Holmes N.E., Turnidge J.D., Munckhof W.J., et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011, 204:340-347.
14. Choi E.Y., Huh J.W., Lim C.M., et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011, 37:639-647.
15. Maclayton D.O., Suda K.J., Coval K.A., York C.B., Garey K.W. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006, 28:1208-1216.
16. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
17. Sader H.S., Rhomberg P.R., Jones R.N. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:3162-3165.
18. Mewara A., Gautam V., Kaur H., et al. In vitro evaluation of antibiotics for methicillin-resistant Staphylococcus aureus from north India. Indian J Med Res 2014, 139:319-322.
19. Dabul A.N., Camargo I.L. Molecular characterization of methicillin-resistant Staphylococcus aureus resistant to tigecycline and daptomycin isolated in a hospital in Brazil. Epidemiol Infect 2014, 142:479-483.
20. Levine D.P. Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 2008, 62(Suppl 3):iii35-iii39.
21. Stevens D.L., Ma Y., Salmi D.B., et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007, 195:202-211.